Luliza Cream contains Luliconazole 1% w/w, an imidazole antifungal agent indicated for the topical treatment of superficial fungal infections such as dermatophytosis, candidiasis, and pityriasis versicolor. Luliconazole exerts its antifungal effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This cream is effective against a broad spectrum of dermatophytes, yeasts, and molds. It is typically applied once daily to the affected area and surrounding skin after cleansing and drying, ensuring complete coverage. The duration of treatment varies depending on the infection type but generally ranges from one to two weeks. Luliza Cream is well tolerated, with minimal local adverse effects such as mild burning, itching, or irritation reported infrequently. It is contraindicated in patients with known hypersensitivity to Luliconazole or any excipients in the formulation. Use during pregnancy and lactation should be under medical supervision. As a topical agent, systemic absorption is minimal, reducing the risk of systemic side effects. Luliza Cream offers an effective and convenient option for managing superficial fungal infections, promoting rapid symptom relief and resolution of infection.